See more : ENPLUS Co., Ltd. (074610.KS) Income Statement Analysis – Financial Results
Complete financial analysis of CanBas Co., Ltd. (4575.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CanBas Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Inter Industries Plus Ltd (ININ.TA) Income Statement Analysis – Financial Results
- Repco Home Finance Limited (REPCOHOME.NS) Income Statement Analysis – Financial Results
- MEGA International Development Co.,Ltd. (5529.TWO) Income Statement Analysis – Financial Results
- CGG BSA 1 (CGGBS.PA) Income Statement Analysis – Financial Results
- Axis Bank Limited (AXISBANK.NS) Income Statement Analysis – Financial Results
CanBas Co., Ltd. (4575.T)
About CanBas Co., Ltd.
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 108.95M | 110.00M |
| Cost of Revenue | 984.00M | 671.00M | 608.00M | 430.00M | 442.00M |
| Gross Profit | -984.00M | -671.00M | -608.00M | -321.06M | -332.00M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | -294.69% | -301.82% |
| Research & Development | 983.00M | 671.04M | 607.78M | 430.24M | 442.21M |
| General & Administrative | 57.00M | 294.92M | 238.66M | 226.38M | 234.60M |
| Selling & Marketing | 134.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 191.00M | 294.92M | 238.66M | 226.38M | 234.60M |
| Other Expenses | -896.00M | -9.00K | -63.14M | 6.00K | -816.00K |
| Operating Expenses | 278.00M | 965.96M | 846.44M | 656.62M | 676.80M |
| Cost & Expenses | 1.26B | 965.96M | 846.44M | 656.62M | 676.80M |
| Interest Income | 32.00K | 21.00K | 17.00K | 38.00K | 159.00K |
| Interest Expense | 0.00 | 1.17M | 5.68M | 7.50M | 5.00M |
| Depreciation & Amortization | 1.26B | -315.93M | -2.21M | 62.00K | -1.89M |
| EBITDA | 53.65M | -1.24B | -848.65M | -522.28M | -566.54M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -502.65% | -516.99% |
| Operating Income | -1.26B | -965.97M | -846.44M | -547.67M | -566.80M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -502.70% | -515.27% |
| Total Other Income/Expenses | 54.00M | -277.86M | -7.89M | 17.89M | -4.74M |
| Income Before Tax | -1.21B | -1.24B | -854.33M | -529.78M | -571.54M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -486.29% | -519.58% |
| Income Tax Expense | 1.00M | 1.25M | 1.25M | 1.25M | 1.25M |
| Net Income | -1.21B | -1.24B | -855.58M | -531.03M | -572.79M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -487.43% | -520.72% |
| EPS | -67.87 | -83.03 | -88.32 | -70.02 | -83.64 |
| EPS Diluted | -67.87 | -83.03 | -88.32 | -70.02 | -83.64 |
| Weighted Avg Shares Out | 17.81M | 14.98M | 9.69M | 7.58M | 6.85M |
| Weighted Avg Shares Out (Dil) | 17.81M | 14.98M | 9.69M | 7.58M | 6.85M |
Source: https://incomestatements.info
Category: Stock Reports